Intravenous zoledronic acid in postmenopausal women with low bone mineral density

Ian R. Reid, Jacques P. Brown, Peter Burckhardt, Zebulun Horowitz, Peter Richardson, Ulrich Trechsel, Albert Widmer, Jean Pierre Devogelaer, Jean Marc Kaufman, Philippe Jaeger, Jean Jacques Body, Maria Luisa Brandi, Johann Broell, Raffaele Di Micco, Andrea Riccardo Genazzani, Dieter Felsenberg, Joachim Happ, Michael J. Hooper, Jochen Ittner, Georg LebHans Mallmin, Timothy Murray, Sergio Ortolani, Alessandro Rubinacci, Maria Sääf, Goran Samsioe, Leon Verbruggen, Pierre J. Meunier

Research output: Contribution to journalArticlepeer-review


Background. Bisphosphonates are effective agents for the management of osteoporosis. Their low bioavailability and low potency necessitate frequent administration on an empty stomach, which may reduce compliance. Gastrointestinal intolerance limits maximal dosing. Although intermittent intravenous treatments have been used, the optimal doses and dosing interval have not been systematically explored. Methods. We studied the effects of five regimens of zoledronic acid, the most potent bisphosphonate, on bone turnover and density in 351 postmenopausal women with low bone mineral density in a one-year, randomized, double-blind, placebo-controlled trial. Women received placebo or intravenous zoledronic acid in doses of 0.25 mg, 0.5 mg, or 1 mg at threemonth intervals. In addition, one group received a total annual dose of 4 mg as a single dose, and another received two doses of 2 mg each, six months apart. Lumbar-spine bone mineral density, was the primary end point. Results. There were similar increases in bone mineral density in all the zoledronic acid groups to values for the spine that were 4.3 to 5.1 percent higher than those in the placebo group (P

Original languageEnglish
Pages (from-to)653-661
Number of pages9
JournalNew England Journal of Medicine
Issue number9
Publication statusPublished - Feb 28 2002

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Intravenous zoledronic acid in postmenopausal women with low bone mineral density'. Together they form a unique fingerprint.

Cite this